Featuring a summary of the Open Pharma team’s trip to Evidence-Based Medicine Live 2019, the potential use of Literature Programming to improve research transparency, a new data depot project in India and the lack of institutional incentives for researchers to publish open access
Featuring the latest results from the Good Pharma Scorecard, the newest signatories to DORA, incentives for sharing data and potential barriers to mandating open access.
Featuring the predatory market for fake science, the paywall surrounding Cabell’s blacklist and the success of medRxiv
Featuring concerns over predatory journals infiltrating PubMed, priorities for Plan S, new guidelines for open peer review and the first full open access agreement for Springer Nature
Featuring a new database of journal editorial policies, improvements in the perceived transparency and credibility of industry-sponsored research, an analysis of institutional open access, feedback on Plan S and an analysis of open access policies of leading medical journals.
Featuring the role of the scientific community in maximizing the impact of metadata, the value of plain-language summaries, an alternative open access publishing model and the growing support for Plan U
Featuring new methods for linking data sets to authors, the upcoming launch of medRxiv and a summary of the revised Plan S guidelines.
Featuring the rising tide of article processing charges and preprints, the changes to the ways in which journals are judged and the limited value of social media in increasing the reach of research
Featuring the development of a new evidence framework for discussing hot open science topics that can be used to address misinformation in scientific publishing, the introduction of transparent manuscript-handling processes, and making the costs of clinical trials publicly available.
Featuring the benefits of open data, why the public should be involved in scientific research and countries that are leading the way in open access publishing.